Skip to content
10-Q

Quarterly Report

Rapid Therapeutic Science Laboratories, Inc.

0001393905-23-000312

← back to feed
Filed
Aug 14, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2023 · Aug 14, 2023 8.83M sh
Capex Q2 2023 · Jun 30, 2023 $0
Capex Q2 2023 · Jun 30, 2022 $354.8K
Operating Cash Flow Q2 2023 · Jun 30, 2023 −$49.14K
Operating Cash Flow Q2 2023 · Jun 30, 2022 −$634.25K
Cash And Equivalents Q2 2023 · Jun 30, 2023 $2.16K
Cash And Equivalents Q2 2023 · Dec 31, 2022 $0
Stockholders Equity Q2 2023 · Jun 30, 2023 −$2.74M
Stockholders Equity Q2 2023 · Dec 31, 2022 −$3.14M
Current Liabilities Q2 2023 · Jun 30, 2023 $4.43M
Current Liabilities Q2 2023 · Dec 31, 2022 $4.97M
Total Liabilities Q2 2023 · Jun 30, 2023 $4.81M
Total Liabilities Q2 2023 · Dec 31, 2022 $5.4M
Current Assets Q2 2023 · Jun 30, 2023 $317.88K
Current Assets Q2 2023 · Dec 31, 2022 $233.19K
Total Assets Q2 2023 · Jun 30, 2023 $2.07M
Total Assets Q2 2023 · Dec 31, 2022 $2.25M
Eps Basic Q2 2023 · Jun 30, 2023 $0.01
Eps Basic Q2 2023 · Jun 30, 2023 $0.03
Eps Basic Q2 2023 · Jun 30, 2022 $0.00
Eps Basic Q2 2023 · Jun 30, 2022 −$0.21
Sga Expense Q2 2023 · Jun 30, 2023 $97.74K
Sga Expense Q2 2023 · Jun 30, 2023 $190.04K
Sga Expense restated Q2 2023 · Jun 30, 2022 $122.38K
Sga Expense restated Q2 2023 · Jun 30, 2022 $905.78K
Gross Profit Q2 2023 · Jun 30, 2023 $0
Gross Profit Q2 2023 · Jun 30, 2023 $0
Gross Profit Q2 2023 · Jun 30, 2022 $0
Gross Profit Q2 2023 · Jun 30, 2022 $0
Cost Of Revenue Q2 2023 · Jun 30, 2023 $0
Cost Of Revenue Q2 2023 · Jun 30, 2023 $0
Cost Of Revenue Q2 2023 · Jun 30, 2022 $0
Cost Of Revenue Q2 2023 · Jun 30, 2022 $0
Revenue Q2 2023 · Jun 30, 2023 $0
Revenue Q2 2023 · Jun 30, 2023 $0
Revenue Q2 2023 · Jun 30, 2022 $0
Revenue Q2 2023 · Jun 30, 2022 $0